Stuart Hogarth
Biographic Data
| ID | 247397 |
|---|---|
| NAME | Stuart Hogarth |
| GIVEN NAMES | Stuart |
| FAMILY NAME | Hogarth |
| SIGNATURE | HOGARTH S |
| AFFILIATIONS | King's College London |
| ORCID | 0000-0001-6796-8815 |
| VERIFIED | Yes |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 21 |
| AUTHOR COUNT | 7 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2010 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 2 |
Multidisciplinary perspectives on the regulation of diagnostic technologies
Regulatory niches: Diagnostic reform as a process of fragmented expansion. Evidence from the UK 1990-2018
The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine
Pharmacogenetic tests provide genetic data to tailor drug treatment and were widely predicted to be one of the first fruits of the Human Genome Project. In the mid‐2000s, the US Food and Drugs Administration (FDA) became an advocate for pharmacogenetic testing, but its efforts to build a market for this new technology brought the agency into dispute with other regulatory actors over the type of evidence needed for the adoption of pharmacogenetic …
Gene Jockeys: Life science and the rise of biotech enterprise
Biotechnology is the Peter Pan of technoscience, somehow forever young; always, it seems, connected with the novel and the emergent. Nevertheless, it is old enough to have a history. Nicholas Rasmu
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
Regulatory experiments and transnational networks: The governance of pharmacogenomics in Europe and the United States
Pharmacogenomics is the use of genomic science to study human variability in drug response. Proponents of pharmacogenomics suggest that it will lead to a new era of personalized medicine through a fundamental transformation in the drug discovery and development process. Uncertainty about the regulatory standards and processes for this emergent technology have been widely cited as an obstacle to more widespread and rapid adoption of pharmacogenomi…
Negotiating the boundary between medicine and consumer culture: Online marketing of nutrigenetic tests
Genomics researchers and policy makers have accused nutrigenetic testing companies--which provide DNA-based nutritional advice online--of misleading the public. The UK and USA regulation of the tests has hinged on whether they are classed as "medical" devices, and alternative regulatory categories for "lifestyle" and less-serious genetic tests have been proposed. This article presents the findings of a qualitative thematic analysis of the webpage…
Negotiating the boundary between medicine and consumer culture: Online marketing of nutrigenetic tests
Genomics researchers and policy makers have accused nutrigenetic testing companies--which provide DNA-based nutritional advice online--of misleading the public. The UK and USA regulation of the tests has hinged on whether they are classed as "medical" devices, and alternative regulatory categories for "lifestyle" and less-serious genetic tests have been proposed. This article presents the findings of a qualitative thematic analysis of the webpage…
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine
Pharmacogenetic tests provide genetic data to tailor drug treatment and were widely predicted to be one of the first fruits of the Human Genome Project. In the mid‐2000s, the US Food and Drugs Administration (FDA) became an advocate for pharmacogenetic testing, but its efforts to build a market for this new technology brought the agency into dispute with other regulatory actors over the type of evidence needed for the adoption of pharmacogenetic …
Multidisciplinary perspectives on the regulation of diagnostic technologies
Regulatory niches: Diagnostic reform as a process of fragmented expansion. Evidence from the UK 1990-2018
Regulatory experiments and transnational networks: The governance of pharmacogenomics in Europe and the United States
Pharmacogenomics is the use of genomic science to study human variability in drug response. Proponents of pharmacogenomics suggest that it will lead to a new era of personalized medicine through a fundamental transformation in the drug discovery and development process. Uncertainty about the regulatory standards and processes for this emergent technology have been widely cited as an obstacle to more widespread and rapid adoption of pharmacogenomi…
Negotiating the boundary between medicine and consumer culture: Online marketing of nutrigenetic tests
Genomics researchers and policy makers have accused nutrigenetic testing companies--which provide DNA-based nutritional advice online--of misleading the public. The UK and USA regulation of the tests has hinged on whether they are classed as "medical" devices, and alternative regulatory categories for "lifestyle" and less-serious genetic tests have been proposed. This article presents the findings of a qualitative thematic analysis of the webpage…
Regulatory experiments and transnational networks: The governance of pharmacogenomics in Europe and the United States
Pharmacogenomics is the use of genomic science to study human variability in drug response. Proponents of pharmacogenomics suggest that it will lead to a new era of personalized medicine through a fundamental transformation in the drug discovery and development process. Uncertainty about the regulatory standards and processes for this emergent technology have been widely cited as an obstacle to more widespread and rapid adoption of pharmacogenomi…
Gene Jockeys: Life science and the rise of biotech enterprise
Biotechnology is the Peter Pan of technoscience, somehow forever young; always, it seems, connected with the novel and the emergent. Nevertheless, it is old enough to have a history. Nicholas Rasmu
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine
Pharmacogenetic tests provide genetic data to tailor drug treatment and were widely predicted to be one of the first fruits of the Human Genome Project. In the mid‐2000s, the US Food and Drugs Administration (FDA) became an advocate for pharmacogenetic testing, but its efforts to build a market for this new technology brought the agency into dispute with other regulatory actors over the type of evidence needed for the adoption of pharmacogenetic …
Multidisciplinary perspectives on the regulation of diagnostic technologies
Regulatory niches: Diagnostic reform as a process of fragmented expansion. Evidence from the UK 1990-2018
Biology (5 works) · Political science (5 works) · Sociology (5 works) · Medicine (4 works) · Social science (4 works) · Biomedical Ethics and Regulation (3 works) · Corporate governance (3 works) · Health Systems, Economic Evaluations, Quality of Life (3 works) · Law (3 works) · Politics (3 works)